BI shoots for further growth in China
This article was originally published in Scrip
Executive Summary
European and US markets might be Boehringer Ingelheim's biggest resources but the German drug maker is aiming to further increase its presence in China, according to Klaus Mendla, BI's global licensing head, central nervous system (CNS).